Welcome to our dedicated page for Candel Therapeutics news (Ticker: CADL), a resource for investors and traders seeking the latest updates and insights on Candel Therapeutics stock.
Candel Therapeutics, Inc. (CADL) is a Massachusetts-based biotechnology company, also known as Advantagene, Inc., specializing in the development of cutting-edge immuno-oncology platforms aimed at treating solid tumors. The company's focus is on leveraging the body's immune system to combat cancer through innovative viral immunotherapies.
At the core of Candel Therapeutics' technology are two proprietary platforms: the Gene Mediated Cytotoxic Immunotherapy (GMCI™) platform and the RQNestin34.5 platform. Designed as an 'off-the-shelf' solution, GMCI™ aims to generate a personalized and precise immune response against cancer, utilizing the patient's own immune system. The RQNestin34.5 platform, on the other hand, is centered around the use of genetically modified herpes simplex virus (HSV) constructs to target and destroy cancer cells.
As a clinical-stage biopharmaceutical company, Candel Therapeutics is dedicated to translating its scientific advancements into viable treatments for patients. The company has made substantial progress with its platforms, demonstrating promising results in clinical studies aiming to establish the efficacy and safety of these novel therapies.
Among the company's recent highlights is its presentation at the American Society of Clinical Oncology (ASCO), where it shared significant updates on its ongoing projects. Candel Therapeutics continues to engage in strategic partnerships and collaborations to advance its mission of making effective cancer treatments accessible to patients globally.
Candel Therapeutics is committed to maintaining robust investor relations, offering transparent updates and clear communication about its financial health, project milestones, and future directions. The company's leadership frequently engages with stakeholders to ensure alignment with their goals and expectations.
For the latest news and detailed financial information, investors and interested parties can contact Theodore Jenkins, Vice President of Investor Relations and Business Development, at tjenkins@candeltx.com or Kyle Evans, Account Director at ICR Westwicke, at CandelPR@westwicke.com.
Candel Therapeutics announced on April 17, 2023, that the FDA has granted fast track designation for its investigational viral immunotherapy CAN-2409 combined with valacyclovir and pembrolizumab. This designation aims to expedite the drug's development for patients with late-stage non-small cell lung cancer (NSCLC) resistant to first-line therapies. CAN-2409 targets patients without molecular driver mutations and aims to enhance survival rates and delay disease progression. Clinical trial data revealed a 77% disease control rate in a subset of patients with previous treatment failures. The company plans to present updated data from the ongoing Phase 2 trial in the third quarter of 2023, showcasing the potential of CAN-2409 in treating various solid tumors.
FAQ
What is the current stock price of Candel Therapeutics (CADL)?
What is the market cap of Candel Therapeutics (CADL)?
What does Candel Therapeutics, Inc. specialize in?
What are the main platforms developed by Candel Therapeutics?
How does the GMCI™ platform work?
What is unique about the RQNestin34.5 platform?
Is Candel Therapeutics a clinical-stage company?
What recent achievements has Candel Therapeutics made?
Who can I contact for investor relations at Candel Therapeutics?
Who handles media inquiries for Candel Therapeutics?
What types of cancer are targeted by Candel Therapeutics' platforms?
Where is Candel Therapeutics based?
